- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04767217
Malaria Therapeutic Efficacy Study, Rwanda
Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children With Uncomplicated Clinical Malaria in Rural Rwanda
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial medicines should be routinely carried out and data made available for decision-making due to the threat of emergence and spread of artemisinin resistance in malaria-endemic countries, especially in Africa. The Rwandan Ministry of Health (MOH) in 2006 adopted WHO-approved artemether-lumefantrine (ALN) as the first-line drug for the treatment of uncomplicated Plasmodium falciparum malaria. A clinical trial carried out in 2004-2005 in Rwanda showed that ALN was very efficacious in children although efficacy varied in different parts of the country. ALN efficacy was shown to remain high in TES conducted in 2012-2015 and in 2018. However, both studies found a molecular marker of parasite resistance to artemisinin (included delayed parasite clearance associated with artemisinin resistance in one site in 2018) and both studies also found high prevalence of markers associated with tolerance to lumefantrine. The clinical efficacy of ALN therefore needs to be regularly monitored in Rwanda to ensure this first line treatment is still efficacious. Given the detection of antimalarial resistance markers in recent TES, it is also important for Rwanda MOH to determine the efficacy an additional ACT that could be considered for adoption as a second line or alternative first line treatment. This study will monitor the efficacy of ALN (which has been used in Rwanda for the last 14 years) and dihydroartemisinin-piperaquine (DHA-PPQ), another WHO-approved ACT for the treatment of uncomplicated malaria which has not been used in Rwanda.
In line with the WHO recommendation, Jhpiego Impact Malaria project in Rwanda, with funding and technical oversight from US President's Malaria Initiative (PMI) through USAID and CDC, will be supporting the Rwanda MOH Malaria and Other Parasitic Diseases Unit (MOPDD) of the Rwanda Biomedical Center (RBC) to conduct a TES to monitor the efficacy of ALN and DHA-PPQ in children with uncomplicated clinical malaria in rural Rwanda. The study is being conducted by Rwanda MOH MOPDD, with technical support and funding by PMI-USAID through the Jhpiego Impact Malaria project in Rwanda.
Objective: To evaluate the efficacy of artemether-lumefantrine (ALN) and dihydroartemisinin-piperaquine (DHA-PPQ) in children with uncomplicated clinical malaria in rural Rwanda
Study Sites: The study will be conducted in three sentinel sites - Rukara, Bugarama and Masaka rural health centers- where antimalaria efficacy studies are always carried out in Rwanda because of the intensity of malaria transmission. Different levels of artemisinin resistance have been identified in two of these three (Rukara and Bugarama) in previous studies. At each site, there will be two arms: one for ALN and one for DHA-PPQ.
Study Design: The study will be a two-arm, open-label trial in which patients (children aged 6 months to 59 months) with uncomplicated P. falciparum malaria will be treated with supervised doses of ALN or DHA-PPQ. Children will be followed for 28 days after treatment for ALN and 42 days after DHA-PPQ. Data on molecular markers of artemisinin resistance will be collected at all sites. The study will be conducted at three sites in Rwanda with historically different efficacy profiles to antimalarials, including ACTs.
The primary endpoint is the clinical and parasitological cure by day 28 (ALN) and day 42 (DHA-PPQ) post-treatment.
Study Period: March 2021 to October 2022
Sample Size: At each site, 88 patients per treatment arm (allowing for 20% loss to follow-up) would be enrolled. In total, we will enrol 528 patients in our study.
Treatment(s) and follow-up: All children enrolled in the study will be admitted to a health centre for three days to ensure adherence to treatment regimen, and detect possible adverse events. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate ALN efficacy, and over a 42-day follow-up period to evaluate DHA-PPQ efficacy.
Exploratory endpoints: to characterize molecular markers of artemisinin and partner drug resistance in all three sites and the clinical (parasite clearance) and in vitro phenotypes of resistance in two of the three study sites: Rukara and Masaka.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bugarama, Rwanda
- Bugarama health center
-
Masaka, Rwanda
- Masaka health center
-
Rukara, Rwanda
- Rukara health center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children aged 6 months to 59 months old
- Monoinfection with P. falciparum and parasitaemia of 1,000 - 100,000 asexual parasites per µl
- Axillary temperature 37.5 °C or history of fever in the preceding 24 hours before recruitment
- Ability to swallow oral medication
- Haemoglobin ≥7.0 g/dL at admission
- Informed consent from guardian/parent of patient
- Parent/guardian agrees to bring the patient for planned follow-up visits at day 7, 14, 21, 28, 35, and 42 (35 and 42 in DHA-PPQ arm only)
- Ability for the child to be admitted to a health center for inpatient blood testing, observation and treatment for three days
Exclusion Criteria:
- Danger signs of severe malaria or signs of severe malaria
- Other underlying diseases (cardiac, renal, hepatic diseases)
- Severe malnutrition according to WHO child growth standards (WHO, 2006), children - with marasmus or oedematous malnutrition
- History of allergy to study drugs
- A clear history of receiving any antimalarial treatment in the preceding 72 hours
- Ongoing prophylaxis with drugs having antimalarial activity, such as cotrimoxazole for the prevention of Pneumocisti jirovici pneumonia in children born to HIV+ women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: artemether-lumefantrine (ALN)
|
Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
|
Active Comparator: dihydroartemisinin-piperaquine (DHA-PPQ)
|
dihydroartemisinin-piperaquine (DHA-PPQ)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients (in the artemether-lumefantrine arm) with clinical and parasitological cure (i.e. free of malaria symptoms and parasites) assessed clinically and via microscopy and rapid diagnostic test
Time Frame: By day 28 post-treatment
|
By day 28 post-treatment
|
Number of patients (in the dihydroartemisinin-piperaquine arm) with clinical and parasitological cure (i.e. free of malaria symptoms and parasites) assessed clinically and via microscopy and rapid diagnostic test
Time Frame: By day 42 post-treatment
|
By day 42 post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients (in the artemether-lumefantrine arm) that developed molecular markers of drug (artemisinin) resistance (assessed via phenotype tests)
Time Frame: By day 28 post-treatment
|
By day 28 post-treatment
|
Number of patients (in the dihydroartemisinin-piperaquine arm) that developed molecular markers of drug (artemisinin) resistance (assessed via phenotype tests)
Time Frame: By day 42 post-treatment
|
By day 42 post-treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00014153
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Malaria
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia
-
U.S. Army Office of the Surgeon GeneralU.S. Army Medical Research and Development Command; Military Infectious Diseases...CompletedFalciparum Malaria | Uncomplicated MalariaKenya, Thailand
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Johns Hopkins Bloomberg School of Public HealthTropical Diseases Research CentreActive, not recruitingUncomplicated Falciparum MalariaZambia
-
University of OxfordMahidol University; Medicines for Malaria VentureWithdrawnUncomplicated Falciparum MalariaCambodia
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompleted
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
Clinical Trials on artemether-lumefantrine (ALN)
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
University of OxfordUniversity of KinshasaCompleted
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRecruitingHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda
-
Novartis PharmaceuticalsCenters for Disease Control and PreventionCompletedMalariaUnited States
-
NovartisCompletedMalaria | FalciparumBenin, Kenya, Mali, Mozambique, Tanzania
-
Centers for Disease Control and PreventionIfakara Health Research and Development CentreCompleted